Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29962224 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL9190336 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6075919 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6075522 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9195378 | 0.81 | MTNR1A (0.75) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9192842 | 0.81 | MTNR1A (0.75) | MTNR1AMTNR1B | |
| SCHEMBL21315657 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL29961769 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6076317 | 0.78 | MTNR1A (0.46) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8757567 | 0.78 | MTNR1A (0.66) | MTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-1206943-B1 | MATRIX ADHERING TO NASAL MUCOSA | TAKEDA PHARMACEUTICAL (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| WO-2008083204-A2 | MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| EP-0527687-B1 | Novel arylethylamin derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-11-22 | — | — | EP | disclosed |
| US-5380750-A | Arylethylamine compounds | ADIR ET COMPAGNIE (FR) | 1995-01-10 | — | — | US | disclosed |
| US-5308866-A | Treatment of melatonin related disorders, sleep disorders, psychological disorders | ADIR ET COMPAGNIE (FR) | 1994-05-03 | — | — | US | disclosed |
| US-5276051-A | Treatment of melatoninergic system, antiischemic agents and skin disorders using aminoalkylindole compounds | ADIR ET COMPAGNIE (FR) | 1994-01-04 | — | — | US | disclosed |
| EP-0527687-A2 | Novel arylethylamin derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | MTNR1A 1/4885MTNR1B 2/4885ALDH1A1 2230/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885ALDH1A1 2234/4885 |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | MTNR1A 1/4885MTNR1B 4/4885ALDH1A1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.